Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Galecto Inc (GLTO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Galecto's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.710 -0.001    -0.08%
04:03:34 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 22,441
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.700 - 0.740
Type:  Equity
Market:  United States
Galecto 0.710 -0.001 -0.08%

Galecto Inc Company Profile

 
Get an in-depth profile of Galecto Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

13

Equity Type

ORD

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Contact Information

Address Ole Maaloes Vej 3 Copenhagen N
Copenhagen, 2200
Denmark
Phone 45 70 70 52 10
Fax -

Top Executives

Name Age Since Title
Hans T. Schambye 57 2020 Co-Founder, President, CEO & Director
Carl S. Goldfischer 64 2020 Independent Chairman of the Board
Chau Quang Khuong 48 2015 Independent Director
Jayson Donald Alexander Dallas 56 2020 Independent Director
Anne Prener 66 2021 Independent Director
Mark Thursz - - Member of Clinical Advisory Board – Liver Cirrhosis
Stephen A. Harrison - - Member of Clinical Advisory Board – Liver Cirrhosis
Aaron Gerds - - Member of the Clinical Advisory Board - Myelofibrosis
Claire Harrison - - Member of the Clinical Advisory Board - Myelofibrosis
William L. Redmond - - Member of Clinical Advisory Board – Oncology
Raajit Rampal - - Member of the Clinical Advisory Board - Myelofibrosis
Adam Mead - - Member of the Clinical Advisory Board - Myelofibrosis
Amit D. Munshi 56 2020 Independent Director
Jonathan Fallowfield - - Member of Clinical Advisory Board – Liver cirrhosis
Roy Steven Herbst 61 - Member of Clinical Advisory Board – Oncology
Søren Møller 57 2020 Independent Director
David Shapiro 70 2020 Independent Director
John Mascarenhas - - Member of the Clinical Advisory Board - Myelofibrosis
Alexander Maximiliaan Marie Eggermont - - Member of Clinical Advisory Board – Oncology
Michael Charlton - - Member of Clinical Advisory Board – Liver cirrhosis
Federico Cappuzzo - - Member of Clinical Advisory Board – Oncology
Massimo Pinzani - - Member of Clinical Advisory Board – Liver Cirrhosis
Jasmohan Bajaj - - Member of Clinical Advisory Board – Liver cirrhosis
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GLTO Comments

Write your thoughts about Galecto Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email